Cesca Therapeutics Inc. (NASDAQ:KOOL)‘s stock had its “hold” rating reaffirmed by stock analysts at Maxim Group in a research note issued to investors on Friday, May 12th.
The analysts wrote, “Summary Cesca announced some strategic shuffling internally. Cesca will operate as two divisions; Thermogenesis which will handle hardware / device business and Cesca focused on the development of therapeutics. The company will target growth of the device business (which is really what the company was, prior to the merger with Totipotent). We view the device business as a breakeven (at best case) business and not fundamentally attractive (given the high costs and relatively low margins) associated with the business. Management did however talk about adapting the technology to have utility in the CAR-T space. On the Therapeutics side the company highlighted their recent N=17 trial in CLI. The data was published in a peer reviewed journal .””
Shares of Cesca Therapeutics (NASDAQ:KOOL) traded down 3.29% during trading on Friday, hitting $2.94. The stock had a trading volume of 39,319 shares. The company’s market cap is $29.11 million. Cesca Therapeutics has a 12 month low of $2.41 and a 12 month high of $7.39. The stock has a 50-day moving average price of $3.10 and a 200 day moving average price of $3.05.
A hedge fund recently raised its stake in Cesca Therapeutics stock. Vanguard Group Inc. increased its stake in shares of Cesca Therapeutics Inc. (NASDAQ:KOOL) by 34.6% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 61,521 shares of the biotechnology company’s stock after buying an additional 15,828 shares during the period. Vanguard Group Inc. owned about 0.62% of Cesca Therapeutics worth $200,000 as of its most recent filing with the SEC. Institutional investors own 2.42% of the company’s stock.
About Cesca Therapeutics
Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
What are top analysts saying about Cesca Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cesca Therapeutics Inc. and related companies.